Memoran

Quick links to important sections

Memoran

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Memoran

Quick Facts

Property Description
Active ingredient Phosphatidylserine (PS)
Form Capsule or Tablet (Oral preparation)
Pharmacological class Nootropic, Neuroprotector, Phospholipid
Common use Support for cognitive function and memory in adults
Origin Endogenous compound, typically derived from plant lecithin

What Type of Compound is Memoran?

Memoran is an orally administered preparation containing the active ingredient Phosphatidylserine (PS), which is fundamentally classified as an endogenous phospholipid. This means the compound is a crucial fat-soluble component naturally present in the human body, highly concentrated in the brain's neuronal cell membranes. Memoran is generally categorized as a neuroprotector and nootropic due to its role in maintaining central nervous system health. Phosphatidylserine is a subject of research regarding its potential for improving cognitive function.

Composition and Available Forms

The core composition of Memoran features L-Phosphatidylserine, a specific serine glycerophospholipid required for effective cell signaling. Contemporary products are manufactured via enzymatic conversion from plant-derived sources, such as soy or sunflower lecithin. This reliance on a well-defined, single-active ingredient—L-Phosphatidylserine—is a key characteristic of the preparation. Memoran is supplied as an oral preparation, most commonly found in capsule or tablet form, designed for convenient systemic absorption intended for adults.

General Purpose and Mechanism Principle

The general purpose of Memoran is to support overall brain health and optimize functions such as memory and mental acuity. Its fundamental mechanism principle involves stabilizing and maintaining the fluidity of the neuronal membrane, which is vital for efficient communication between nerve cells. By contributing to the structural integrity of these membranes, Memoran assists in the underlying physiological processes necessary for sustained cognitive performance and neural resilience.

What side effects are possible with Memoran?

Memoran: Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety constraints for Memoran, based strictly on governmental regulatory documents (such as those from the FDA or EMA).


Adverse Reaction Profile

Adverse reactions are formally categorized by frequency using a standardized framework (e.g., ICH/EMA bands) and by the body system affected (System-Organ Class or SOC):

Frequency Classification Examples of Types of Reactions
Very Common (1 in 10 or more) Nausea, headache, dry mouth
Common (1 in 100 to less than 1 in 10) Dizziness, fatigue, diarrhea
Uncommon (1 in 1,000 to less than 1 in 100) Rash, elevated liver enzymes, insomnia
Rare (1 in 10,000 to less than 1 in 1,000) Agitation, hypotension

Major System-Organ Classes involved include Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders.


Serious Safety Considerations

Serious Adverse Reactions (SARs), which are clinically significant events, are documented in regulatory labeling. These rare but important events may include severe hypersensitivity reactions like Anaphylaxis or severe organ-specific toxicity such as Hepatic Failure. Patients should be aware of the signs of these serious events.

Population-Specific Safety Notes are defined for certain patient groups where the safety profile may differ or require caution, such as in patients with severe Renal or Hepatic Impairment, and specific considerations for Older Adults.


Official Safety Constraints

Regulatory documents list certain Contraindications that restrict Memoran's use (e.g., in patients with known severe hepatic impairment) and may mandate Safety-related Monitoring. The official label may also note specific side effects that are more common during the initiation of therapy, reflecting time- or exposure-related patterns.

Overdose and Emergency Response

Memoran Overdose and when to seek help

Overdose Scope

The official regulatory literature indicates that overdose with Memoran (Phosphatidylserine) is unlikely to cause serious adverse reactions. The documented clinical manifestations of high exposure are primarily limited to reports of stomach upset (gastrointestinal discomfort) and insomnia (sleeplessness), affecting the gastrointestinal and central nervous systems.

No specific dose levels or population-based overdose considerations (such as for renal impairment or age) are formally stated in the official labeling.

Emergency-Response Statements

Regulatory guidance directs that symptoms are expected to resolve with discontinuation of the compound. Management in the event of overexposure should involve symptomatic and supportive treatment, as no specific antidote is known or formally listed in the regulatory information.

Overdose Classifications (High-Level)

Based on available data, the official classification designates a low acute risk, as serious outcomes are determined to be unlikely.

When Immediate Medical Help is Required: Individuals must seek medical advice for any unexpected, persistent, or severe symptoms that occur following a suspected overexposure. No mandatory hospital monitoring requirements are formally documented in official labeling.

Connection to the overall overdose profile

The documented overdose profile is defined by a low acute risk and the absence of severe adverse reactions in official reports. This classification establishes that the primary management is product discontinuation and supportive care, with the mandated help-seeking condition being a general requirement to consult medical professionals for any severe or unexpected clinical changes.

Therapeutic Uses of Memoran

What Memoran Treats: Main Uses and Benefits

Memoran (Phosphatidylserine) is applied across domains where additional symptomatic support is needed for cognitive function and tension. This use is often relevant in contexts marked by increased discomfort or tension, particularly those related to symptoms linked to organ-specific functional stress and the aging process. The compound is associated with managing cognitive impairment and age-associated memory loss.

The compound may assist with symptom clusters related to difficulties in short-term recall, slowed information retrieval, focus deficits, and a subjective sense of mental fatigue. This benefit is relevant in conditions involving recurrent or episodic manifestations, or those characterized by periods of heightened symptoms.

Quick Fact: Relief for Cognitive Symptom Burden

Memoran may be part of symptomatic management for symptoms related to neurological activity in older adults. It is commonly used to help with memory and concentration deficits, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Memoran?

The eligibility profile for Memoran (Phosphatidylserine) is defined by official regulatory statements and documented limitations concerning patient status, age, and product source.


Eligibility Scope

  • Populations for whom use is allowed: Use is documented as generally acceptable in Adults and Older Adults, the primary population of study. Use is also cited as possibly safe for defined periods in Children aged 4 to 18 years.
  • Populations for whom use is not recommended: Use is not recommended for Pregnant or Breastfeeding individuals due to a lack of sufficient reliable safety data.
  • Populations for whom use is contraindicated: Use is strictly contraindicated in patients with a known Hypersensitivity to Phosphatidylserine or any component of the formulation.
  • Age-related eligibility rules: Safety and use are not established for Infants and Young Children under 4 years of age.
  • Pregnancy and lactation eligibility status: The status is officially classified as Not Recommended due to insufficient reliable safety information for these groups.
  • Eligibility-related restrictions: Use is prohibited when the formulation is derived from bovine cortex (cow brain) due to regulatory concerns regarding the risk of transmitting prion diseases.

Eligibility Classifications

  • Eligibility severity classification: Classification includes Contraindicated (Hypersensitivity), Prohibited (Bovine source material), Not Recommended (Pregnancy/Lactation), and Not Established (Children under 4).
  • Regulatory basis: Eligibility data is primarily drawn from US FDA GRAS notices, NIH monographs, and authoritative supplement/medical food labeling.

Resulting eligibility structure

Official eligibility statements:

  • The medicine is formally contraindicated for any individual with a known hypersensitivity to the active ingredient.
  • Use is prohibited when the product source is bovine cortex.
  • Use is not recommended for pregnant or breastfeeding individuals.

Connection to the overall eligibility profile: Official regulatory documents define eligibility by establishing absolute contraindications based on allergy and source material, while imposing a "not recommended" status for physiological states due to insufficient data. Eligibility is documented as permissible for adult and geriatric populations, reflecting the focus of its established use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Memoran may interact with several medicinal products and other substances, altering either the exposure of Memoran or the co-administered drug, or leading to combined physiological effects. These documented interactions are categorized based on their mechanism and clinical significance.

Pharmacodynamic and Mechanistic Conflicts

Interaction Type Interacting Agents Regulatory Constraint
Additive NMDA-Antagonism Other NMDA-antagonists (e.g., amantadine, ketamine, dextromethorphan) Avoid concomitant use to mitigate increased central nervous system-related adverse reactions, including risk of pharmacotoxic psychosis.
Additive Spasmolytic Effect Antispasmodic agents (dantrolene, baclofen) Effects may be modified; dose adjustments may be necessary.

Pharmacokinetic Alterations

Mechanism Interacting Agents Consequence
Reduced Renal Clearance Substances that alkalize urine (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) Clearance of Memoran is substantially reduced under alkaline conditions, risking accumulation; use with caution.
Competition for Renal Cationic Transport Substrates of the renal cationic transport system (e.g., cimetidine, ranitidine, quinidine) Potential risk of increased Memoran plasma levels.

Additionally, the effects of dopaminergic agonists, L-dopa, and anticholinergics may be enhanced. The effects of barbiturates and neuroleptics may be reduced. When co-administered with oral anticoagulants like warfarin, close monitoring of coagulation status (e.g., INR) is advisable due to isolated reports of changes in the coagulation profile.

Mechanism of Action

Memoran is a low-to-moderate affinity, uncompetitive antagonist that primarily targets the N-methyl-D-aspartate (NMDA) receptor, a ligand-gated ion channel for glutamate in the central nervous system. Its principal action involves voltage-dependent blockade of the receptor-operated cation channels. Memoran binds within the ion channel pore, which is distinct from the glutamate binding site.

This interaction functions as an open-channel blockade, preferentially binding and occluding the channel when it is pathologically overactivated. This mechanism inhibits excessive current flow and the resulting pathologically elevated intracellular calcium influx, particularly via extrasynaptic NMDA receptors. The fast on/off kinetics and low affinity of Memoran permit the continuation of normal, physiological synaptic transmission while selectively modulating sustained, excessive glutamate signaling. This downstream modulation regulates neuronal excitability across relevant neural circuits.

Dosage and Administration Information

Instruction Map: How to use Memoran — Official Administration Guidelines

Administration Scope

Feature Guideline
Route of administration: Oral administration (systemic absorption).
Dosing schedule: Standard Adult Total Daily Dose: 100 mg to 300 mg per day.
Timing in relation to meals (if applicable): May be taken with or without meals.
Preparation requirements (if applicable): Oral solids (capsules/tablets) must be swallowed whole with water and not crushed or chewed.
Age-group administration rules: Permitted for Adults 18 years and older. Pediatric use requires the explicit direction of a physician.
Missed-dose rules: Not uniformly documented; standard procedural practice is to resume the next scheduled dose.
Special procedural conditions: Dosing may be divided up to three times daily to maintain consistent levels.

Instruction Classifications (High-Level)

Classification Description
Administration method type: Oral
Frequency pattern: Daily use, often in a divided schedule.
Basis for guidelines: Structured monographs and guidelines.
Use-context constraints: Intended for continuous long-term use, with an initial assessment period of six to twelve weeks defined in clinical protocols.

Resulting Procedural Structure

Official step sequence:

  • Intake: Swallowing the specified oral dosage form (capsule or tablet) with water.
  • Dose Division: Administering the total daily dose (100 mg-300 mg) up to three times per day.
  • Duration: Continuing administration daily over a prolonged course (e.g., six weeks minimum).

Connection to the overall use protocol (2–4 sentences): The official administration guidelines establish the oral route and define the 100 mg to 300 mg total daily range as the standardized quantity for adult use. This protocol outlines a divided-dose schedule for consistent intake and frames the medication's use as a continuous, long-term pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Memoran (Phosphatidylserine)


Evidence for Use in Age-Associated Cognitive Decline and Memory Complaints

Memoran (Phosphatidylserine) was studied for people, typically older adults, who experienced subjective memory complaints or were diagnosed with mild memory difficulties. Studies was observed in populations with Age-Associated Memory Impairment or Mild Cognitive Impairment (MCI).

Studies monitored outcomes reflecting daily functioning or activity level, using specialized tests to examine immediate recall, learning ability, and recognition. Findings describe patterns observed in the studies where differences in measured outcomes was observed in some studies compared to those receiving the placebo. Research provides insight into short-term changes measured during the study period, primarily over short or intermediate timeframes, generally lasting up to six months.

However, the evidence quality varies across studies, and findings were mixed. The certainty remains low for many research questions because of these mixed findings. Data are still emerging to explore the consistency of findings for contemporary Memoran formulations.

Evidence Supporting Mental Acuity and Cognitive Performance

Research explored Memoran in smaller, short-term trials involving healthy young to middle-aged adults. These studies explored short-term symptom changes and focused on episodes where cognitive demands were higher. Studies monitored outcomes related to systemic or functional imbalance, including measures of focus, attention, and executive function.

Studies monitored performance on mental tasks and also examined related markers, such as specific brain activity patterns. Research provides insight into short-term changes, but the sample sizes were modest. Because the evidence is limited, these results apply only to the populations studied in the existing research.

What is Still Uncertain About Memoran Research

A key limitation across the evidence base is the inconsistency of results reported, often depending on the specific source or manufacturing process of the compound. Furthermore, follow-up durations were limited, leaving a lack of definitive data on long-term outcomes. Long-term effects are not fully established, and comparative evidence is lacking in many of the core studies. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Phosphatidylserine - Alzheimer's Drug Discovery Foundation (Evidence Summary)

Frequently Asked Questions (FAQ)

Common questions about Memoran (FAQ)

Q: Can Memoran be taken at any time of day?

Official guidelines state that the preparation may be taken with or without meals. The dosing schedule is defined as daily, often administered in a divided schedule throughout the day. This schedule structure describes flexibility in the timing of administration.


Q: Will Memoran affect my sleep?

Regulatory safety documents list insomnia (difficulty sleeping) as an Uncommon adverse reaction, meaning it is reported in less than 1 in 100 users. Persistent changes in sleep pattern are typically addressed by a healthcare provider.


Q: Are there any long-term effects of taking Memoran?

Official research reviews indicate that the long-term effects are not fully established. The follow-up durations in existing studies have been limited. Research continues to explore the consistency and duration of observed outcomes over extended periods.


Q: Is it normal to feel a change in energy levels after starting Memoran?

Regulatory safety documentation lists fatigue as a Common adverse reaction, meaning it is reported in 1 in 10 to less than 1 in 100 users. This is a common pattern observed when beginning the preparation.


Q: Does Memoran affect blood pressure?

The regulatory safety profile lists hypotension (low blood pressure) as a Rare adverse reaction, reported in less than 1 in 1,000 users. Other significant changes in blood pressure are not generally noted among the common or very common side effects.


Q: Does Memoran cause stomach upset?

Yes, official safety documents include gastrointestinal events as documented adverse reactions. Nausea is classified as Very Common, and diarrhea is classified as Common among reported side effects.


Q: Does Memoran change how other medicines are absorbed?

Official information on drug interactions notes that Memoran's body processing (specifically its clearance) can be affected by certain substances, such as those that make the urine more alkaline. However, the regulatory documentation does not provide specific details on whether Memoran changes the way other medicines are absorbed into the body.


Q: Do I need to avoid any specific foods while on Memoran?

The official administration guidelines state that the preparation may be taken with or without meals. The core regulatory information does not list any specific foods or drinks that must be strictly avoided during use.


Q: Does Memoran cause weight gain?

Based on official regulatory safety documents, weight gain is not listed among the commonly reported side effects. The official adverse reaction profiles focus on other system effects.


Q: Is it true that Memoran can interact with over-the-counter pain relievers?

The regulatory interaction profile focuses on specific medicinal classes, such as NMDA-antagonists and urine alkalizing agents. Common over-the-counter pain relievers are not explicitly mentioned in the core regulatory monographs as having a known interaction.


Q: Is Memoran considered a type of antidepressant?

No. According to official regulatory documentation, Memoran (Phosphatidylserine) is classified as a Nootropic and a Neuroprotector phospholipid. It is not classified as an antidepressant.


Q: Is Memoran a controlled substance?

No. Memoran (Phosphatidylserine) is classified by the FDA as Generally Recognized As Safe (GRAS) for use in food and supplements. It is not listed as a scheduled or controlled substance.


Q: What does official research say about Memoran’s effect on [specific outcome]?

Studies and official information indicate that research has examined Memoran's effect on various specific cognitive functions. These include measures of immediate recall, learning ability, recognition, focus, attention, and executive function.


Q: Can Memoran interact with vitamins or herbal supplements?

Official regulatory reviews note that Memoran's action may interact with other substances, including supplements, that either increase the chemical acetylcholine or those that block its effects (known as anticholinergics).


Q: Does Memoran have a 'black box' warning?

A 'Black Box Warning,' also known as a Boxed Warning, is the strictest warning required by the FDA for certain products. There is no mention of a 'Black Box Warning' in the available regulatory documents or safety constraints for Memoran.


Q: Is Memoran a habit-forming drug?

No. Memoran is not classified as a controlled substance and is not listed in official regulatory documents as having known habit-forming or dependency properties.


Q: Can I drive while using Memoran?

Regulatory guidance does not specifically address driving. However, documented common side effects include dizziness and fatigue. These symptoms are listed as common side effects.


Q: What should be discussed with a doctor before starting Memoran?

The regulatory profile includes conditions that may require discussion with a healthcare provider before starting Memoran. This covers known hypersensitivity to the ingredient, pre-existing conditions like severe renal or hepatic impairment, and the potential need for safety-related monitoring during administration.


Q: What happens if I accidentally take two doses of Memoran?

Specific overdose instructions are not provided in the core documents. However, official safety data notes that side effects such as insomnia and stomach upset have been observed, especially at total daily doses exceeding the standard daily range.


Q: Does Memoran require a special prescription?

No. Memoran (Phosphatidylserine) is widely available as a dietary supplement. It is classified by the FDA as Generally Recognized As Safe (GRAS), which means it typically does not require a prescription.

How should Memoran be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Memoran (Phosphatidylserine) must strictly adhere to regulatory guidelines for oral preparations to maintain product integrity and ensure safety.

Storage Requirement Condition
Temperature Store at controlled room temperature (e.g., 59°F to 86°F or 15°C to 30°C).
Protection Keep the product in its original container, tightly closed, and protect from excessive heat and moisture.
Child Safety Must be kept out of the sight and reach of children.

For disposal, unused or expired Memoran should not be flushed down a toilet or drain. Regulatory guidance recommends utilizing a drug take-back program. If a take-back program is unavailable, mix the product with an unappealing substance, seal it in a container, and dispose of it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Memoran found in:

A-Z Index: